Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

The president-elect made the announcement on Truth Social on Sunday. ABC News’ MaryAlice Parks discusses President Joe Biden's invitation for President-elect Donald Trump to visit the White ...